TTrialPathMatch Me to Trials
← Back to trials
RecruitingCongenital Heart Disease in Children

Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery

Eligible age

0.3–4.9 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The proposed study will be a prospective, randomized, double blind, placebo controlled trial to compare the use of a continuous infusion versus intermittent ketorolac on postoperative patients in the pediatric cardiovascular ICU. We intend to determine if the continuous infusion leads to a decreased utilization of opiates when compared to intermittent ketorolac.

Sponsor: Phoenix Children's Hospital

You may qualify if…

  • ✓ 1. All patients aged 3 months to 4 years 11months admitted post operatively to the CVICU during the time period in which the study will be ongoing
  • ✓ 2. Initiation of study medication within the first 12-24 hours post-operatively
  • ✓ 3. The cardiovascular attending of record after review of the intraoperative course and post-operative laboratories determines the patient will receive Ketorolac for pain control

You may not qualify if…

  • ✕ 1. Patients that have acute kidney injury, as defined by the letter "I" in the pRIFLE criteria.
  • ✕ 2. History of allergy or sensitivity reaction to ketorolac or any NSAID medications.
  • ✕ 3. Requiring mechanical circulatory support (ECMO) or continuous renal replacement therapy (CRRT) within the first 48 hours post-operatively
  • ✕ 4. Orthotopic heart transplantation
  • ✕ 5. Clinically significant bleeding
  • ✕ 6. Patients with known pre-operative medical renal disease, renal transplantation history, congenital or acquired renal abnormality or deformity

Where it's recruiting

Arizona

Phoenix

Source: ClinicalTrials.gov · NCT04040452 · last updated 2026-08-12

Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surge · TrialPath